Tower Research Capital LLC (Trc) Atea Pharmaceuticals, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.39 Billion
- Q3 2025
A detailed history of Tower Research Capital LLC (Trc) transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 5,325 shares of AVIR stock, worth $15,762. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,325
Previous 8,492
37.29%
Holding current value
$15,762
Previous $30,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding AVIR
# of Institutions
123Shares Held
49.3MCall Options Held
54KPut Options Held
98K-
Black Rock Inc. New York, NY9.12MShares$27 Million0.0% of portfolio
-
Bml Capital Management, LLC Zionsville, IN7.47MShares$22.1 Million19.85% of portfolio
-
Tang Capital Management LLC San Diego, CA4.83MShares$14.3 Million0.64% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.71MShares$13.9 Million0.0% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA2.49MShares$7.36 Million2.31% of portfolio
About Atea Pharmaceuticals, Inc.
- Ticker AVIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,258,600
- Market Cap $246M
- Description
- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...